Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.

doi:10.1016/j.lungcan.2021.08.011

Paper

Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.

Published Aug 27, 2021 · H. Mumblat, A. Martinez-Conde, O. Braten

Lung cancer

Q1 SJR score

31

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

TTFields at 150 kHz effectively reduce Fanconi Anemia-BRCA pathway proteins and increase DNA damage in malignant pleural mesothelioma cells, enhancing chemotherapy treatment efficacy.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.

Sign up to use Study Snapshot

References

Citations

Treatment of Pleural Mesothelioma: ASCO Guideline Update.

The ASCO guideline update provides evidence-based recommendations for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with pleural mesothelioma.

Protocol for applying Tumor Treating Fields in mouse models of cancer using the inovivo system

This protocol outlines the proper application of Tumor Treating Fields (TTFields) in mouse tumor models using the inovivo system, allowing for concurrent treatment with standard cancer therapies.

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.

TTFields therapy shows efficacy in a broad range of patients with glioblastoma, with a tolerable safety profile, and shows potential as an adjuvant treatment in oncology.

Personalized optimization strategy for electrode array layout in TTFields of glioblastoma.

Optimizing the placement of electrode arrays in TTFields using the ISABO algorithm can enhance electric field intensity and treatment coverage in glioblastoma patients, offering a more effective personalized treatment approach.

Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance

TTFields can sensitize homologous recombination proficient and resistant ovarian cancer cells to carboplatin or PARPi treatment, potentially mitigating drug resistance in ovarian cancer treatment.

Tumor treating fields suppress tumor cell growth and neurologic decline in models of spinal metastases

Tumor treating fields (TTFields) can effectively suppress tumor growth and neurologic decline in spinal metastases, potentially benefiting patients with treatment-refractory spinal metastases.

Theory and application of TTFields in newly diagnosed glioblastoma

TTFields therapy, using intermediate-frequency and low-intensity alternating electric fields, can improve prognosis and potentially prolong survival in newly diagnosed glioblastoma patients.